Literature DB >> 26421708

Short-term outcomes of intracorporeal esophagojejunostomy using the transorally inserted anvil versus extracorporeal circular anastomosis during laparoscopic total gastrectomy for gastric cancer: a propensity score matching analysis.

Xin Lu1, Yanfeng Hu1, Hao Liu1, Tingyu Mou1, Zhenwei Deng1, Da Wang1, Jiang Yu2, Guoxin Li3.   

Abstract

BACKGROUND: To assess the short-term outcomes of intracorporeal Roux-en-Y esophagojejunostomy using the transorally inserted anvil (OrVil) compared with extracorporeal circular Roux-en-Y anastomosis during laparoscopic total gastrectomy (LTG) for gastric cancer.
METHODS: From January 2011-April 2014, a total of 165 consecutive patients with gastric cancer underwent either intracorporeal Roux-en-Y esophagojejunostomy (n = 25) using the Orvil or extracorporeal circular anastomosis (n = 140) during LTG. After generating propensity scores with six covariates, including gender, age, body mass index (BMI), Eastern Cooperative Oncology Group performance status, tumor location, and tumor size, 25 patients undergoing the OrVil method (intracorporeal group) were one-to-one matched with 25 patients undergoing the extracorporeal method (extracorporeal group). The short-term outcomes were compared between the two groups.
RESULTS: Both groups were balanced regarding baseline variables. The total operative time was not significantly different between the two groups (216.5 ± 24.9 min versus 224.0 ± 30.5 min, P = 0.344), whereas either the duration of anvil insertion (9.9 ± 2.4 min versus 12.9 ± 2.0 min, P < 0.001) or reconstruction completion (44.4 ± 9.4 min versus 50.1 ± 5.4 min, P = 0.012) in the intracorporeal group was less. The mean length of minilaparotomy in the intracorporeal group was shorter (5.6 ± 0.4 cm versus 7.2 ± 1.7 cm, P < 0.001). No significant differences were observed in intraoperative complication rate, estimated blood loss, length of proximal margin, or postoperative recovery course (including the time to first flatus, liquid resumption, liquid, and soft diet) between the two groups. No patients suffered from anastomosis-related complications. The overall morbidity rates of 28.0% in the intracorporeal group and 32.0% in the extracorporeal group were comparable (P = 0.758).
CONCLUSIONS: Intracorporeal Roux-en-Y esophagojejunostomy using the transorally inserted anvil system may be a safe procedure during LTG for gastric cancer. However, a longer follow-up in a well-designed randomized controlled trial is necessary to more thoroughly evaluate this technique.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Esophagojejunostomy; Gastric cancer; Laparoscopic total gastrectomy; OrVil; Propensity score matching

Mesh:

Year:  2015        PMID: 26421708     DOI: 10.1016/j.jss.2015.08.013

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  10 in total

1.  Efficacy of totally laparoscopic compared with laparoscopic-assisted total gastrectomy for gastric cancer: A meta-analysis.

Authors:  Song Wang; Mei-Lan Su; Yang Liu; Zhi-Ping Huang; Ning Guo; Tian-Jin Chen; Zhong-Hui Zou
Journal:  World J Clin Cases       Date:  2020-03-06       Impact factor: 1.337

2.  Oncological feasibility of laparoscopic subtotal gastrectomy compared with laparoscopic proximal or total gastrectomy for cT1N0M0 gastric cancer in the upper gastric body.

Authors:  Yosuke Kano; Manabu Ohashi; Satoshi Ida; Koshi Kumagai; Souya Nunobe; Takeshi Sano; Naoki Hiki
Journal:  Gastric Cancer       Date:  2019-03-04       Impact factor: 7.701

3.  Impact of stepwise introduction of esophagojejunostomy during laparoscopic total gastrectomy: a single-center experience in Japan.

Authors:  Daiki Yasukawa; Tomohide Hori; Yoshio Kadokawa; Shigeru Kato; Takafumi Machimoto; Toshiyuki Hata; Yuki Aisu; Maho Sasaki; Yusuke Kimura; Yuichi Takamatsu; Tatsuo Ito; Tsunehiro Yoshimura
Journal:  Ann Gastroenterol       Date:  2017-05-11

4.  Comparison of Intracorporeal and Extracorporeal Esophagojejunostomy after Laparoscopic Total Gastrectomy for Gastric Cancer: A Meta-Analysis Based on Short-Term Outcomes.

Authors:  Xue-Yong Zheng; Yu Pan; Ke Chen; Jia-Qi Gao; Xiu-Jun Cai
Journal:  Chin Med J (Engl)       Date:  2018-03-20       Impact factor: 2.628

5.  Laparoscopic gastrectomy in obese gastric cancer patients: a comparative study with non-obese patients and evaluation of difference in laparoscopic methods.

Authors:  Ke Chen; Yu Pan; Shu-Ting Zhai; Jia-Qin Cai; Qi-Long Chen; Ding-Wei Chen; Yi-Ping Zhu; Yu Zhang; Ya-Ping Zhang; Hendi Maher; Xian-Fa Wang
Journal:  BMC Gastroenterol       Date:  2017-06-19       Impact factor: 3.067

Review 6.  Current status of laparoscopic total gastrectomy.

Authors:  Yoshihiko Kawaguchi; Kensuke Shiraishi; Hidenori Akaike; Daisuke Ichikawa
Journal:  Ann Gastroenterol Surg       Date:  2018-09-17

7.  A Modified Anastomosis Technique for Esophagojejunostomy after Laparoscopy-Assisted Total Gastrectomy: A Single Team Preliminary Experience.

Authors:  Zehui Wu; Bing Wang; Gang Liu; Jiaju Lu; Chengxiong Zhang; Fangzheng Chen; Lianghui Shi; Aman Xu
Journal:  Gastroenterol Res Pract       Date:  2022-01-18       Impact factor: 2.260

8.  Comparisons of short-term and survival outcomes of laparoscopy-assisted versus open total gastrectomy for gastric cancer patients.

Authors:  Xin-Zu Chen; Shao-Yong Wang; Yin-Su Wang; Zi-Han Jiang; Wei-Han Zhang; Kai Liu; Kun Yang; Xiao-Long Chen; Lin-Yong Zhao; Meng Qiu; Hong-Feng Gou; Zong-Guang Zhou; Jian-Kun Hu
Journal:  Oncotarget       Date:  2017-04-10

Review 9.  Digestive tract reconstruction options after laparoscopic gastrectomy for gastric cancer.

Authors:  Jian Shen; Xiang Ma; Jing Yang; Jian-Ping Zhang
Journal:  World J Gastrointest Oncol       Date:  2020-01-15

10.  Comparison of the short-term outcomes between totally laparoscopic total gastrectomy and laparoscopic-assisted total gastrectomy for gastric cancer: a meta-analysis.

Authors:  Gang Liao; Ziwei Wang; Wei Zhang; Kun Qian; Sandrie Mariella Mac; Hui Li; Zhen Huang
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.